Published On: Tue, Jun 23rd, 2015

Current Trade News Review: Tyco International (NYSE:TYC), Realty Income (NYSE:O), Array Biopharma (NASDAQ:ARRY), AGCO (NYSE:AGCO)

During Monday’s current trade, Tyco International PLC (NYSE:TYC)’s shares incline 0.15% to $40.20.

Tyco International PLC (TYC) declared that its Board of Directors has declared a quarterly dividend of $0.205 per share for the fourth quarter of fiscal 2015, payable on August 19, 2015, to shareholders of record at the close of NYSE trading on July 24, 2015.

Tyco International Ltd. designs, sells, installs, and services security, fire detection, suppression, and life safety products worldwide. It operates in three segments: North America Installation & Services, Rest of World Installation & Services, and Global Products. Its electronic security systems comprise detection devices; asset protection and security administration systems; anti-theft systems; access control solutions, such as integrated security administration systems, access control solutions applications, alarm administration panels, door controllers, readers, keypads, and cards; video system solutions, such as digital video administration systems, matrix switchers and controllers, digital multiplexers, programmable cameras, monitors, and liquid crystal interactive displays; and burglar alarms and interactive security systems, such as alarm control panels, keypads, sensors, and central station receiving equipment for homes and businesses.

Realty Income Corp (NYSE:O)‘s shares gain 0.20% to $46.16, during the current trading session Monday’s, hitting its highest level.

Realty Income Corporation (O), The Monthly Dividend Company®, recently declared its Board of Directors has declared an enhance in the company’s common stock monthly cash dividend to $0.19 per share from $0.1895 per share. The dividend is payable on July 15, 2015 to shareholders of record as of July 1, 2015. This is the 81st dividend enhance since Realty Income’s listing on the NYSE in 1994. The new monthly dividend amount represents an annualized dividend amount of $2.28 per share as contrast to the previous annualized dividend amount of $2.274 per share.

The Board of Directors also declared a dividend on the company’s Monthly Income Class F preferred stock. The monthly dividend amount of $0.138021 on the Class F preferred shares is payable on July 15, 2015 to shareholders of record as of July 1, 2015. The annualized dividend amount for the Class F preferred shares is $1.65625 per share.

Realty Income Corporation is a publicly traded real estate investment trust. It invests in the real estate markets of the United States. The firm makes investments in commercial real estate. Realty Income Corporation was founded in 1969 and is based in Escondido, California.

In an afternoon trade, Array Biopharma Inc (NASDAQ:ARRY)‘s shares surge 1.54% to $7.89.

Array Biopharma Inc (ARRY) was showcased at the 2015 annual meeting of the American Society of Clinical Oncology (ASCO). At the meeting, preliminary data for the combination of binimetinib and encorafenib from a Phase 1b/2 dose escalation and expansion study in patients with BRAF-mutant melanoma who are BRAF inhibitor treatment naive were shared during an oral presentation. Results from the study indicate that binimetinib and encorafenib may be safely combined and show encouraging clinical activity comprising with MEK/BRAF inhibitor expectations in patients with BRAF-mutant melanoma who are BRAF inhibitor treatment naive. In addition, a differentiated safety profile relative to other MEK/BRAF inhibitor combinations is emerging in the dose range presently being used in the Phase 3 COLUMBUS trial. Array anticipates updated BRAF melanoma data from the ongoing Phase 2 combination trial (LOGIC-2) of binimetinib and encorafenib followed by the addition of a third targeted agent identified based on genetic testing at the time of progression will be presented to a scientific conference later this year. LOGIC-2 utilizes the same dose of binimetinib and encorafenib presently being studied in the COLUMBUS trial.

Preliminary data from the study also indicate that in combination with binimetinib, encorafenib was tolerated at doses up to 600 mg, twice its single-agent maximum tolerated dose. At the 400/450 mg dose of encorafenib, with few grade 3 / 4 events and an 11 percent incidence of pyrexia and photosensitivity, a differentiated safety profile relative to other MEK/BRAF inhibitor combinations is emerging.

Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific. The company’s products in Phase III clinical trials comprise Binimetinib and Encorafenib for the treatment of cancer. Its clinical programs in Phase II clinical trial comprise ARRY-797, a p38 program for Lamin A/C-related dilated cardiomyopathy; and ARRY-502, a CRTh2 antagonist to treat Th2-driven allergic disease.

AGCO Corporation (NYSE:AGCO), during its Monday’s current trading session 3.26% gain and closed at $54.41.

AGCO Corporation (AGCO) has opened its first Future Farm and Learning Center in Africa, near Lusaka, Zambia. The Future Farm will assist empower local communities to develop a sustainable food production system and to enhance farm productivity by implementing modern farming techniques. The 150-hectare farm is divided into a diverse range of demonstration crop areas all cultivated, planted and harvested using the company’s full-line of agricultural equipment.

Africa’s population is predictable to rise to two billion by 2050. As a result, the need for inclusive, sustainable mechanization and training, and to inspire the next generation to move into agriculture is now more than ever. AGCO’s aim is to provide agricultural solutions to all African farmers. Mechanization is a key ingredient to increasing agricultural productivity in Africa. Moreover, other constraints such as lack of improved seed, the right blends of fertilizers, the need for favorable trade and land policies, quality post-harvest administration solutions and functional markets for harvested crops also need to be addressed.

AGCO Corporation manufactures and distributes agricultural equipment and related replacement parts worldwide. The company offers tractors, counting high horsepower tractors that are used on larger farms primarily for row crop production; utility tractors for small- and medium-sized farms, in addition to for specialty agricultural industries comprising dairy, livestock, orchards, and vineyards; compact tractors for small farms, specialty agricultural industries, landscaping, and residential uses; and combines used in harvesting grain crops, such as corn, wheat, soybean, and rice products.

DISCLAIMER:

This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.

All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.

Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.

Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.

 

[“source – wsnewspublishers.com”]